This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
1 Apr 2011

Medivation & Astellas Start Prostate Cancer Drug Study

The study is designed to compare MDV3100 with bicalutamide, a commonly used anti-androgen, and is expected to enrol approximately 370 patients in North America and Europe.

Medivation and Astellas Pharma have announced that they have treated the first patient in a Phase II study of MDV3100, a triple-acting oral androgen receptor antagonist to fight advanced prostate cancer.

 

This is the first of two Phase II trials that are being initiated to evaluate the potential benefit of MDV3100 in a broad spectrum of prostate cancer patients. The second of the new Phase II trials will study MDV3100 in an even earlier-stage population, and the trial is expected to begin in the first half of this year.

 

The study is designed to compare MDV3100 with bicalutamide, a commonly used anti-androgen, and is expected to enrol approximately 370 patients in North America and Europe.

Related News